TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04143724: A Phase 2a Study to Evaluate the Safety and Pharmacokinetics of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Sponsor: Celgene · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 99 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,353,200

Rescue Site Savings

+$2,224,400

Unlock Full NCT04143724 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04143724 Rescue Dossier →